How to navigate the CRADA process

A Cooperative Research and Development Agreement (CRADA) is a formal mechanism for a US federal laboratory and a non-federal organisation to undertake joint research. It can connect an Australian company with specialist scientists, equipment, methods or federally developed technology while defining contributions, intellectual property (IP), confidentiality, publication and project governance. It supports research activity rather than serving as a procurement contract or a cash grant to the company.

The opportunity is relevant to Australian companies working in mining, agriculture, manufacturing, healthcare, energy and environmental monitoring. A business in Brisbane may need better ore-sensing, a Melbourne manufacturer may want more reliable inspection, and an Adelaide health researcher may need advanced imaging. These problems can benefit from a national laboratory capability without requiring the company to build every asset internally.

Cross-border participation changes the preparation. Australian teams routinely exchange technical information with overseas partners, yet a CRADA needs stronger controls around confidential know-how, sample handling, personal information and export-controlled technology. The legal entity, ownership chain, signatory authority and intended commercial use should be established before sensitive material is disclosed.

The process is rarely a single application form. It moves from discovery and technical fit, through a proposal and internal review, to negotiation, approval and active research. Treating the stages as one pathway helps a company test fit early, preserve patent options and clarify the eventual commercialisation route.

Start with capability, not a product

Begin by separating a technology listing from a research capability. A US federal laboratory may offer a developed technology, facility, scientific team or enabling method. The Federal Laboratory Consortium connects more than 300 federal laboratories with businesses, entrepreneurs and researchers; its directory and technology locator span seven regional areas and help identify expertise for licensing or commercial partnerships. The federal technology catalogue is a starting point, but a listing does not guarantee that a laboratory will enter a CRADA.

For each candidate, examine the scientific problem, facilities, lead team, patents, licences and government rights. Check whether capacity exists for the proposed period and whether the work fits the laboratory's mission. A specific application is stronger than a broad collaboration request, especially when staff and equipment are limited.

Record a capability map covering the problem, expertise, equipment, expected contribution, deliverables and unresolved questions. This lets an Australian company compare laboratories on the same basis. It also gives a technology transfer office enough detail to identify a technical contact and decide whether an initial discussion is appropriate.

Frame the research question

Turn the business need into a testable research question. State the hypothesis, baseline, method, target performance and time frame. A mining project might test a sensor in dust, vibration and heat; a food producer might measure whether a preservation method retains quality during transport. Clear parameters make results useful to both parties.

For an Australian manufacturing team in Melbourne or Adelaide, a useful analogy is the automated quality inspection example, which shows how off-the-shelf vision software can be evaluated against a defined defect-detection task. The important element is not the brand of software. It is the comparison with current inspection practice, the cost of errors and an agreed threshold for moving from prototype to production.

Describe each side's contribution precisely. The laboratory might provide scientists, a test bed, calibration equipment or historical data; the company might provide samples, domain knowledge, manufacturing access or staff funding. Identify what is out of scope, what happens if a milestone fails, and whether the project is exploratory, validation-oriented or aimed at a deployable prototype. This framing protects the research plan and later IP discussions.

Make the first approach count

Send the first approach to the laboratory's technology transfer office, with the technical lead copied, rather than treating a general enquiry as a binding proposal. A concise concept note should identify the Australian legal entity, problem, requested capability, contribution, timeframe and commercial sector. Include relevant publications or patents, while keeping confidential details out of the initial email.

The laboratory will assess mission alignment, staff availability, facility capacity, prior work, national-security considerations and whether the partner and use case are permissible. A foreign company may receive additional questions about ownership, beneficial ownership, access to controlled technology and data location. An early response should acknowledge those questions and identify which Australian personnel will handle intellectual property, privacy and export-control review.

Australian project teams working across different cities often coordinate through email, shared drives and video meetings. Agree on a primary contact, document repository and meeting rhythm before substantive work begins. Version history and minutes reduce confusion about samples, drawings and results. Ask whether a confidentiality agreement is needed before sending commercially sensitive material.

Negotiate the agreement

A CRADA should be negotiated for the actual collaboration, not copied without review. The agreement normally addresses the parties, purpose, term, authorised representatives, laboratory resources, non-federal contributions, reporting, termination and dispute resolution. Work may be described in a statement of work or annex, with milestones and deliverables attached. Laboratory work or sensitive-material transfer should not begin merely because a commercial team is excited about a possible project.

Intellectual property requires particular care. Separate background IP, which each party brings to the project, from foreground IP, created during it. Negotiate ownership or licensing rights, patent prosecution costs, commercial markets and any laboratory or government rights. Address joint inventions, improvements, experimental data, software, know-how and any right to publish or delay publication for patent protection.

Confidentiality provisions should cover commercial information, unpublished results, samples and personal information, with rules for subcontractors and returning or deleting material at the end. Australian organisations may need to consider the Privacy Act 1988 and the Australian Privacy Principles when personal information is processed, alongside state or territory health-privacy duties where applicable. The agreement should allocate liability, insurance, cybersecurity duties and responsibility for third-party claims.

Approve scope, compliance and deliverables

Translate the concept into an approvable research plan. Set out hypotheses, experimental protocols, sample or data requirements, roles, milestones, acceptance criteria, resource commitments and reporting dates. State what counts as a successful result, including a negative or inconclusive finding. A staged pilot can reduce risk: prove feasibility on a bench, validate under operating conditions, then assess scale, safety and regulatory requirements. Changes to scope, timing or personnel should use a written process.

Export and security review can affect what the project may legally or contractually do. Depending on the technology and end use, US controls under the Export Administration Regulations or International Traffic in Arms Regulations may apply. Australian participants may also check the Strategic Goods Act 1979 and Defence Trade Controls Act 2012, along with sanctions and access restrictions. The plan should identify classification, screening, storage, transmission and a technology control plan before controlled details or equipment cross borders.

Use Australian intellectual-property advice when an invention is made, not after a demonstration. IP Australia can explain filing routes, patentability and the effect of public disclosure, while a patent attorney can assess whether a provisional application or another filing strategy is appropriate. Keep invention records, signed laboratory notebooks and source files; distinguish results owned by a university or prior contractor from material created under the CRADA. Timely filings preserve options while the commercial route is assessed.

Run the research with clear records

During the project, use a governance structure that matches the scale of the work. Name a technical lead and an authorised commercial or legal contact from each party, schedule progress reviews, and maintain a risk register covering equipment, samples, staffing, safety and regulatory approvals. Keep decisions, deviations and changes in one accessible record. A distributed Australian team can maintain momentum through short video meetings and a shared repository with access limited to people who need the information.

Reporting should connect scientific progress with the agreement's obligations. Record results against milestones, document use of laboratory resources, flag emerging inventions promptly and identify anything that could affect patent rights, publication or export compliance. Agree early on pre-publication review, reasonable response times and credit. Before public release, check that the disclosure is accurate and cleared for confidentiality and security obligations.

Safety and ethics remain part of the research record. Obtain institutional, environmental, biosafety or human-subject approvals before the relevant activity, and ensure everyone handling samples or equipment follows agreed protocols. A quality-management system may be needed for medical, aerospace or industrial applications, with traceable measurements and corrective actions. A well-kept CRADA file makes the final report, patent assessment and partner handover more defensible.

Close the project and commercialise carefully

At completion, reconcile technical results with the agreement. Deliver the final report, confirm milestones, list inventions and tangible outputs, return or dispose of samples as required, and document custody of data, software, equipment and records. Check whether post-project rights, reporting duties or confidentiality periods continue. A final meeting with technical and legal contacts can resolve unfinished ownership questions before the relationship moves into licensing or product development.

A CRADA can lead to a licence, collaboration, spin-out or supply relationship, but it does not automatically provide exclusive commercial rights. Use the negotiated ownership and licensing provisions to decide who will develop, manufacture or sell the result, and whether additional performance milestones are required. Review freedom to operate, regulatory approval, manufacturing scale and cross-border tax planning before committing to a launch.

For an Australian organisation, a strong outcome is a traceable partnership built around a real technical result and a credible route to use it. The CRADA file, invention records and laboratory correspondence together provide evidence of contribution, protect valuable know-how and make a later licence or commercial collaboration easier to evaluate.